Do you have advanced Stage III or IV Head and Neck Cancer? You might be able to join a research study. We are looking at new treatments compared to the usual care for your type of cancer.

Do you have incurable, metastatic head and neck squamous cell carcinoma ? If so, you may be able to take part in a study to see if a new drug called Cisplatin is effective.

Are you a young adult who drinks and uses social media? We are holding in-person workshops in downtown Chapel Hill to gather feedback from young adults who drink and use social media. Compensation provided.

We are studying how well a new medicine called Sacituzumab Tirumotecan works by itself and when combined with another medicine called pembrolizumab. We are comparing these treatments to the usual chemotherapy to see which one is better and safer for people with a specific type of breast cancer that has come back or spread and can't be removed by surgery.

This research study seeks to improve the treatment of early-stage breast cancer by examining circulating tumor DNA (ctDNA). CtDNA, a biomarker found in the blood, may indicate the presence of residual disease after initial treatment. The study aims to determine if ctDNA analysis can help doctors personalize adjuvant therapies, such as radiation and systemic therapy, leading to more effective treatment plans. A significant focus is placed on including African American/Black patients, a population often underrepresented in genomic research. By analyzing ctDNA in this group, researchers hope to gain valuable insights into the disease's characteristics and improve treatment outcomes, ultimately reducing disparities in breast cancer care. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

Do you have acid reflux, GERD, or Barrett's Esophagus? Are you having standard of care endoscopies performed? You may be able to participate in a research study testing for Barrett's Esophagus and esophageal cancer. Compensation provided.

In this study, we want to see if a new drug called LBS-007 can help treat or cure leukemia. We want to find out if it is safe and if it works well for people with this disease.

to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.

The purpose of this study is to explore the safety and efficacy of a study drug called Telisotuzumab adizutecan (ABBV-400) in combination with existing therapies in Metastatic Colorectal Cancer (mCRC) patients.

The purpose of this research is to test the safety of NXC-201 (a CAR-T cell targeting the BCMA protein) at different doses in participants with relapsed/refractory AL amyloidosis, and to confirm the best dose for further testing. In addition, the study will evaluate the effectiveness of NXC-201 in treating relapsed/refractory AL amyloidosis